PKCy receptor mediates visceral nociception and hyperalgesia following exposure to PTSD-like stress in the spinal cord of rats

Yu-Qin He¹, Qiang Chen¹, Lei Ji¹, Zheng-Guo Wang¹, Zhi-Hong Bai², Robert L Stephens Jr³ and Min Yang¹*

Abstract

Background: Clinical studies indicate that patients with post-traumatic stress disorder (PTSD) frequently share comorbidity with numerous chronic pain conditions. However, the sustained effects of PTSD-like stress over time on visceral nociception and hyperalgesia have been rarely studied, and the underlying mechanisms of stress-induced modulation of visceral hyperalgesia remain elusive. The purpose of this study was to investigate the characterization of visceral nociception and hyperalgesia over time in rats exposed to PTSD-like stress, and to explore the potential role of protein kinase C gamma (PKCy) in mediating visceral hyperalgesia following exposure to PTSD-like stress.

Results: On day 1, the rats exposed to single-prolonged stress (SPS, an established animal model for PTSD) exhibited an analgesic response and its visceromotor response (VMR) to graded colorectal distention (CRD) at 40 and 60 mmHg was reduced compared with the control group (all \( P < 0.05 \)). On day 6, the VMR returned to the baseline value. However, as early as 7 days after SPS, VMR dramatically increased compared with its baseline value and that in the controls (all \( P < 0.001 \)) and this increase persisted for 28 days, with the peak on day 9. Abdominal withdrawal reflex (AWR) scores were higher in SPS rats than in controls on days 7, 9, 14, 21 and 28 (all \( P < 0.001 \)). Intrathecal administration of GF109203X (an inhibitor of PKC gamma), attenuated the SPS-induced increase in both VMR and AWR scores on days 7, 14, 21 and 28 (all \( P < 0.05 \)). PKCy protein expression determined by immunofluorescence was reduced in the spinal cord within 3 days after the exposure to SPS (\( P < 0.01 \)), which returned to normal levels between days 4 and 6, and significantly increased from day 7, and this increase was maintained on days 14, 21, and 28 (all \( P < 0.001 \)), with the peak on day 9. In addition, Western blotting showed a consistent trend in the changes of PKCy protein expression.

Conclusions: The modified SPS alters visceral sensitivity to CRD, and contributes to the maintenance of visceral hyperalgesia, which is associated with enhanced PKCy expression in the spinal cord. Functional blockade of the PKCy receptors attenuates SPS-induced visceral hyperalgesia. Thus, the present study identifies a specific molecular mechanism for visceral hyperalgesia which may pave the way for novel therapeutic strategies for PTSD-like conditions.

Keywords: Visceral hyperalgesia, Protein kinase C gamma, Post-traumatic stress disorder, Single-prolonged stress, Colorectal distention, Visceromotor response, Spinal cord

* Correspondence: yangmindoctor@gmail.com

¹Department of Gastroenterology, Daping Hospital, Third Military Medical University, 10 Changjiang Branch Road, Daping, Chongqing 400042, China

Full list of author information is available at the end of the article

© 2013 He et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

Post-traumatic stress disorder (PTSD) is a group of symptoms that occur in individuals who have been exposed to life-threatening stressors [1-3]. Epidemiological studies have implicated PTSD-like stress as a trigger of first onset or exacerbation or relapse of symptoms of irritable bowel syndrome (IBS), characterized by hyperalgesia and allodynia [4,5]. Despite the high comorbidity of chronic pain conditions in PTSD patients [6-11], the sustained effects of PTSD-like stress over time on visceral nociception and hyperalgesia have been rarely studied. Furthermore, the molecular mechanisms underlying stress-induced modulation of visceral pain and prolonged visceral hyperalgesia remain unknown. Moreover, limited data on visceral pain processing in this disorder show inconsistent results [9,12,13], highlighting the need for further investigation. Previous studies on PTSD have focused predominantly on the amygdala, medial prefrontal cortex, hippocampus and anterior cingulate of the brain [14-16]. However, there is a growing appreciation that the dorsal horn neurons of the spinal cord are also impacted by the stress, which can last for weeks [17,18]. Thus, spinal sensitization is increasingly accepted as an important component in the maintenance of allodynia and hyperalgesia in various models of chronic pain and stress-induced visceral hypersensitivity [19-22]. The single-prolonged stress (SPS) model, an established animal model for PTSD, mimics some of the physiological and behavioral changes described in PTSD patients, and has been used to examine the therapeutic responses in visceral pain related to the intense stress [9,12,23,24].

The gamma isoform of protein kinase C (PKC\textgamma) is widely distributed throughout the nervous system, particularly in the interneurons of the inner part of lamina II of the dorsal horn, which implies that PKC\textgamma may play a critical role in the nociceptive signaling process [25]. Accordingly, a variety of approaches have been explored to elucidate the potential role of PKC\textgamma as a pain mediator in nociceptive signal transduction [26-29]. It has been demonstrated that PKC\textgamma is involved in many aspects of cellular sensitization, including modulation of channel conductivity, increased trafficking of receptors, and release of excitatory neurotransmitters [30]. PKC\textgamma plays an important role in the sensitization of nociceptive neurons of dorsal horn in certain pain states and thus algesic hypersensitivity in several animal models of visceral pain and visceral injury [9,16,30-32]. PKC\textgamma expression is upregulated under pain conditions resulting from nerve damage or inflammation in animal models [26-29], indicating its involvement in both neuropathic and inflammatory pain. Lower mechanical and thermal hyperalgesia has been observed in PKC\textgamma knock-out mice in response to nerve damage [26,30,33], and spinal block-ade of PKC\textgamma reverses the hyperalgesia induced by subcutaneous formalin, pancreatitis and cutaneous capsaicin [34-37]. Although all these data support a role for PKC\textgamma in visceral pain, it is unknown whether PKC\textgamma also contributes to the maintenance of chronic visceral hyperalgesia over time following exposure to PTSD-like stress. We postulate that PKC\textgamma is the potential mechanism through which spinal sensitization may occur in response to PTSD-like stress.

Therefore, the purpose of this study was to investigate the characterization of visceral nociception and hyperalgesia over time in rats exposed to PTSD-like stress, and to explore the potential role of PKC\textgamma in mediating visceral hyperalgesia following exposure to PTSD-like stress. This study showed that SPS altered visceromotor response (VMR) and abdominal withdrawal reflex (AWR) to graded colorectal distension (CRD) and contributed to the development of delayed visceral hyperalgesia, which is accompanied by PKC\textgamma overexpression. GF109203X (an inhibitor of PKC\textgamma) attenuated the VMR and AWR in SPS-exposed rats. Thus, the present study provides direct evidence for the role of PKC\textgamma in SPS-induced visceral hyperalgesia, and may pave the way for novel therapeutic strategies for PTSD-like stress.

Results

Alteration of VMR to graded CRD over time following exposure to SPS

VMR to CRD was recorded at different time points (baseline, days 1, 6, 7, 10, 14, 21, 28 and 29) after SPS exposure. The baseline VMR to CRD was equivalent between control and pre-SPS groups in a pressure-dependent manner (Figure 1). However, on day 1, SPS-treated rats exhibited an analgesic response, and the VMR to CRD was significantly increased at both 40 and 60 mmHg compared with control rats (0.301 ± 0.012 vs. 0.380 ± 0.014, P = 0.013 and 0.417 ± 0.018 vs. 0.535 ± 0.020, P < 0.001, respectively). On day 6, the VMR returned to the baseline values in SPS rats. However, on day 7, the VMR to CRD was significantly increased at both 40 and 60 mmHg, and the mean area under the curve (AUC) of electromyographic (EMG) signal in SPS rats was significantly increased compared with its baseline value and that in the controls (all P < 0.001). There was a significant increase in the VMR to graded intensities of phasic CRD (40 and 60 mmHg) between day 7 and day 28 compared with baseline value in SPS rats and those in the control rats (all P < 0.001), with the peak on day 9 after SPS exposure. On day 29, the VMR decreased to a level similar to baseline levels (Table 1).

At a distension pressure of 60 mmHg, 87% of the SPS-exposed rats developed an increased VMR 7 days following exposure to SPS; 22%, 38% and 27% exhibited an increase in VMR by 1–50%, 51–100%, and > 101% over the baseline, respectively.
AWR in response to graded CRD over time following exposure to SPS

Visceral pain sensitivity was also determined by measuring the AWR scores in response to graded CRD (10, 20, 40 and 60 mmHg) at various time points (baseline, days 1, 6, 7, 14, 21, 28 and 29 after SPS). The AWR scores were higher in rats exposed to SPS at 40 and 60 mmHg than in control rats on days 7, 9, 14, 21 and 28 (all \( P < 0.001 \)) (Table 2).

Effects of GF109023X on VMR to CRD following exposure to SPS

Since the peaking VMR to phasic CRD (40 and 60 mmHg) was on day 9 after exposure to SPS, we chose this time point to investigate the dose–response effects of GF109023X at doses of 0.05-0.50 nmol/10 μL on VMR to CRD, and determined the effective dose that completely inhibits the response to 60 mmHg CRD, a noxious intensity. When administered intrathecally, GF109023X at low doses ranging from 0.05-0.15 nmol/10 μL did not significantly affect VMR to the graded intensities of phasic CRD. However, at 0.30 nmol/10 μL, GF109023X significantly attenuated VMR to CRD at 40 mmHg in the SPS-treated rats compared with the vehicle group (0.584 ± 0.032 vs. 0.670 ± 0.028, \( P = 0.013 \)); no such effect was observed at 60 mmHg. At 0.50 nmol/10 μL, GF109023X completely inhibited the response to CRD at both 40 mmHg (0.541 ± 0.014 vs. 0.670 ± 0.028, \( P < 0.001 \)) and 60 mmHg (0.681 ± 0.018 vs. 0.896 ± 0.008, \( P < 0.001 \)) in SPS-treated rats compared with the vehicle group and with the low-dose groups (all \( P < 0.001 \)) (Figures 2A & 2B, Table 3).

In addition, intrathecal administration of 0.50 nmol/10 μL of GF109023X 10 min before CRD abolished visceral hyperalgesia and attenuated SPS-induced increase in

---

**Table 1 Visceromotor response (VMR) to phasic ascending colorectal distention (CRD) over time following exposure to single-prolonged stress**

| Group          | 10 mm Hg    | 20 mm Hg    | 40 mm Hg    | 60 mm Hg    |
|----------------|-------------|-------------|-------------|-------------|
| Control (n = 8)| 0.055 ± 0.006 | 0.259 ± 0.013 | 0.380 ± 0.014 | 0.535 ± 0.020 |
| Post-1 day (n = 7) | 0.053 ± 0.007 | 0.230 ± 0.012 | 0.301 ± 0.012\(^\text{V}\) | 0.417 ± 0.018\(^\text{V}\) |
| Post-6 days (n = 8) | 0.047 ± 0.006 | 0.263 ± 0.019 | 0.359 ± 0.012 | 0.536 ± 0.022 |
| Post-7 days (n = 10) | 0.056 ± 0.006 | 0.284 ± 0.020 | 0.617 ± 0.022\(^\text{V}\) | 0.759 ± 0.022\(^\text{V}\) |
| Post-9 days (n = 7) | 0.059 ± 0.007 | 0.329 ± 0.015 | 0.670 ± 0.028\(^\text{V}\) | 0.896 ± 0.008 \(^\text{V}\) |
| Post-14 days (n = 8) | 0.048 ± 0.005 | 0.254 ± 0.037 | 0.653 ± 0.020\(^\text{V}\) | 0.818 ± 0.020 \(^\text{V}\) |
| Post-21 days (n = 10) | 0.053 ± 0.006 | 0.291 ± 0.017 | 0.648 ± 0.021\(^\text{V}\) | 0.823 ± 0.017 \(^\text{V}\) |
| Post-28 days (n = 9) | 0.050 ± 0.005 | 0.312 ± 0.016 | 0.623 ± 0.024\(^\text{V}\) | 0.839 ± 0.026 \(^\text{V}\) |
| Post-29 days (n = 9) | 0.042 ± 0.003 | 0.291 ± 0.021 | 0.450 ± 0.022 | 0.594 ± 0.025 |

All data are expressed as the mean ± S.E.M.

VMR was represented by the mean value of the area under the curve of the electromyographic activity during CRD.

\(^{\text{a}}\) \( P < 0.05 \) compared with Control.

\(^{\text{a}}\) \( P < 0.001 \) compared with Control.

\(^{\text{a}}\) \( P < 0.05 \) compared with post-29 days.
VMR to CRD at 40 and 60 mmHg on days 7, 14, 21 and 28 after SPS, when compared with vehicle injection (all \( P < 0.05 \)) (Figures 3A & 3B). In control rats, GF109203X had no significant effects on the VMR to CRD.

Effects of GF109023X on AWR to CRD following exposure to SPS

We also investigated the dose–response effects of GF109023X on AWR to CRD on day 9 after exposure to SPS. At low-doses (0.05-0.15 nmol/10 μL), GF109023X had no significant effects on AWR to the graded intensities of phasic CRD. However, at 0.30 nmol/10 μL, GF109023X significantly attenuated the AWR to CRD at 40 mmHg in SPS-treated rats compared with the vehicle group (2.825 ± 0.103 vs. 3.186 ± 0.083, \( P = 0.017 \)); no such effect was observed at 60 mmHg. At 0.50 nmol/10 μL, GF109023X completely attenuated the AWR in response to CRD at both 40 and 60 mmHg, with the AWR scores to CRD being significant decreased in SPS-treated rats when compared with the vehicle group (2.744 ± 0.100 vs. 3.186 ± 0.083, \( P = 0.003 \) for 40 mmHg and 3.011 ± 0.353 vs. 3.871 ± 0.161, \( P = 0.005 \) for 60 mmHg), and with the low-dose groups (all \( P < 0.05 \)) (Table 4 and Figures 4A & 4B).

In addition, the administration of GF109023X at 0.50 nmol/10 μL caused a significant reduction of AWR to CRD at 40 and 60 mmHg on days 7, 14, 21 and 28 compared with baseline and vehicle injection (all \( P < 0.05 \)) (Figures 5A & 5B). In control rats, GF109023X had no significant effects on the AWR to CRD.

Spinal PKCy protein expression over time following exposure to SPS as determined by immunofluorescence staining

In the dorsal horn of the spinal cord, PKCy immunostaining formed a dense plexus, consisting of strongly immunoreactive cell bodies and associated dendrites. The most strongly PKCy-immunoreactive neurons were located in the inner plexus of lamina II (iii) and ventral to the plexus in lamina III, whereas weakly stained cells were present in the outer part of lamina II (iio) and in lamina I. By immunofluorescence analysis, SPS-treated rats exhibited a reduced PKCy expression in the dorsal horn of the spinal cord within 3 days after exposure to SPS compared with baseline (\( P < 0.01 \), Figures 6A & 6B); however, those neuronal stores were replenished between days 4 and 6 after exposure to SPS. SPS significantly increased PKCy expression in the dorsal horn of the spinal cord as early as on day 7, compared with the control rats, with the average optical density (AOD) of immunoreactivity being 143.44 ± 2.40 vs. 108.50 ± 3.66, \( P < 0.001 \) (Figure 6C). This increase was maintained on days 14 (148.22 ± 4.02), 21 (147.33 ± 3.77), and 28 (149.11 ± 4.68) in SPS-treated rats compared with the control rats (all \( P < 0.001 \)) (Figures 6D-F, Table 5). A similar trend was noted on day 29 after SPS, but this was not statistically significant (\( P = 0.420 \)). The peak expression of PKCy was reached on day 9 (Figure 6G). In the meantime, there was no marked difference in the PKCy expression in the SPS exposed rats among different time points (all \( P > 0.05 \)). Negative controls (treated without the primary antibody) had no staining.

Spinal PKCy protein expression over time following exposure to SPS as determined by Western blotting

The PKCy protein expression was analyzed with Western blotting from the spinal cord homogenates. On day 1, the relative optical density (ROD) of the PKCy immunoblot bands in the spinal cord was significantly decreased in SPS-exposed rats, compared with the control rats (\( P < 0.001 \)). PKCy expression was significantly increased on as early as day 7 in SPS-exposed rats, and this

Table 2 Abdominal withdrawal reflex score in response to phasic ascending colorectal distention over time following exposure to single-prolonged stress

| Group                  | 10 mm Hg       | 20 mm Hg       | 40 mm Hg       | 60 mm Hg       |
|------------------------|----------------|----------------|----------------|----------------|
| Control (n = 8)         | 1.099 ± 0.120  | 2.050 ± 0.109  | 2.586 ± 0.134* | 2.850 ± 0.132* |
| Post-1 day (n = 7)      | 1.117 ± 0.159  | 2.029 ± 0.157  | 1.942 ± 0.149* | 1.986 ± 0.122* |
| Post-6 days (n = 8)     | 1.170 ± 0.113  | 2.050 ± 0.109  | 3.125 ± 0.096* | 3.625 ± 0.096* |
| Post-7 days (n = 10)    | 1.067 ± 0.072  | 2.090 ± 0.067  | 3.190 ± 0.057* | 3.860 ± 0.134* |
| Post-9 days (n = 7)     | 1.043 ± 0.100  | 2.100 ± 0.079  | 3.186 ± 0.083* | 3.871 ± 0.161* |
| Post-14 days (n = 8)    | 1.100 ± 0.101  | 2.050 ± 0.065  | 3.162 ± 0.065* | 3.650 ± 0.093* |
| Post-21 days (n = 10)   | 1.109 ± 0.081  | 2.040 ± 0.056  | 3.170 ± 0.063* | 3.800 ± 0.089* |
| Post-28 days (n = 9)    | 1.078 ± 0.101  | 2.022 ± 0.061  | 3.222 ± 0.055* | 3.522 ± 0.072* |
| Post-29 days (n = 9)    | 1.080 ± 0.085  | 2.000 ± 0.058  | 2.638 ± 0.091  | 2.800 ± 0.097  |

All data are expressed as the mean ± S.E.M.

* \( P < 0.001 \) compared with Control.

▲ \( P < 0.001 \) compared with post-1 day.

& \( P < 0.001 \) compared with post-29 days.
increase was also maintained on days 14, 21 and 28, compared with the controls (all \( P < 0.001 \)) (Figure 7 and Table 6).

**Discussion**

Clinical studies indicate that PTSD patients frequently share comorbidity with numerous chronic pain conditions. However, only a few studies have examined if subjection to PTSD-like conditions alters visceral nociception and hyperalgesia, which reported decreased or unchanged nociceptive sensitivity [8,9,11]. In addition, the molecular mechanisms underlying stress-induced modulation of visceral hyperalgesia remain elusive. PKC\( \gamma \) as a pain marker has been shown to be important in several animal models of visceral pain, and is thought to play a role in long term hyper-excitability or sensitization in nociceptive neurons.

**Table 3 Effect of GF109203X (GF) on visceromotor response to phasic ascending colorectal distention over time following exposure to single-prolonged stress (SPS)**

| Group                  | 10 mm Hg | 20 mm Hg | 40 mm Hg | 60 mm Hg |
|------------------------|----------|----------|----------|----------|
| Control (n = 8)        | 0.055 ± 0.006 | 0.259 ± 0.013 | 0.380 ± 0.014\(^d\) | 0.535 ± 0.020\(^\dagger\) |
| SPS + Vehicle (n = 7) | 0.059 ± 0.007 | 0.299 ± 0.013 | 0.670 ± 0.028\(^\#\) | 0.896 ± 0.008\(^\#\) |
| SPS + GF (0.05 nmol)  | 0.059 ± 0.004 | 0.293 ± 0.021 | 0.676 ± 0.012\(^\#\) | 0.874 ± 0.010\(^\#\) |
| SPS + GF (0.15 nmol)  | 0.059 ± 0.004 | 0.281 ± 0.017 | 0.666 ± 0.031\(^\#\) | 0.874 ± 0.014\(^\#\) |
| SPS + GF (0.30 nmol)  | 0.054 ± 0.004 | 0.278 ± 0.019 | 0.584 ± 0.032\(^\dagger\) | 0.856 ± 0.015\(^\dagger\) |
| SPS + GF (0.50 nmol)  | 0.053 ± 0.003 | 0.277 ± 0.015 | 0.541 ± 0.014\(^\dagger\) | 0.681 ± 0.018\(^\dagger\) |

All data are expressed as the mean ± S.E.M. *\( P < 0.05 \), and **\( P < 0.001 \), compared with SPS + Vehicle, respectively.

\(^\dagger\)\( P < 0.001 \), compared with SPS + Vehicle.

\(^\#\)\( P < 0.001 \), compared with SPS + GF (0.50 nmol).
of dorsal horn in certain pain states [25-27,29-32]. We hypothesized that PTSD-like stress alters visceral sensitivity and produces visceral hyperalgesia, and spinal activation of PKCγ mediates the development of persistent visceral hyperalgesia following exposure to PTSD-like stress. Therefore, we examined the characterization of visceral nociception and hyperalgesia over time following exposure to PTSD-like stress, and explored the role of PKCγ signaling in the development of stress-induced visceral hyperalgesia at the spinal level and provided novel insights into its underlying molecular mechanisms of stress-related pain modulation.

**Figure 3** Effect of GF109203X (GF) at 0.5 nmol/10 μL on visceromotor response to phasic colorectal distention at 40 mmHg (A) and 60 mmHg (B) following exposure to single-prolonged stress (SPS). All data are expressed as the mean ± S.E.M. (n = 7–10). All *P* < 0.05, compared with the Vehicle group.

**Table 4** Effect of GF109203X (GF) on abdominal withdrawal reflex score in response to phasic ascending colorectal distention over time following exposure to single-prolonged stress (SPS)

| Group                        | 10 mm Hg      | 20 mm Hg      | 40 mm Hg      | 60 mm Hg      |
|------------------------------|---------------|---------------|---------------|---------------|
| Control (n = 8)              | 1.099 ± 0.120 | 2.050 ± 0.109 | 2.588 ± 0.134 | 2.850 ± 0.132 |
| SPS + Vehicle (n = 7)        | 1.043 ± 0.010 | 2.100 ± 0.079 | 3.186 ± 0.083 | 3.871 ± 0.161 |
| SPS + GF (0.05 nmol) (n = 7) | 1.153 ± 0.098 | 2.071 ± 0.102 | 3.229 ± 0.068 | 3.700 ± 0.115 | *<0.05 |
| SPS + GF (0.15 nmol) (n = 8) | 1.030 ± 0.065 | 2.088 ± 0.048 | 3.125 ± 0.084 | 3.575 ± 0.139 | *<0.05 |
| SPS + GF (0.30 nmol) (n = 8) | 1.120 ± 0.087 | 2.038 ± 0.080 | 2.825 ± 0.103 | 3.700 ± 0.118 | *<0.05 |
| SPS + GF (0.50 nmol) (n = 9) | 1.060 ± 0.064 | 1.967 ± 0.067 | 2.744 ± 0.100 | 3.011 ± 0.353 | **<0.01** |

All data are expressed as the mean ± S.E.M.

* *P* < 0.05, and ** *P* < 0.01, compared with SPS + Vehicle, respectively.

* *P* < 0.05, compared with SPS + GF (0.50 nmol).

& *P* < 0.01, compared with SPS + Vehicle.
In present study, we used a previously validated rat model of modified SPS, an established animal model for PTSD [23,24]. The inescapable electric foot shock, which is often employed to produce fear or anxiety and considered a noxious stimulus, was added to the conventional SPS procedures, and reported to significantly enhance conditioned and sensitized fear responses [24]. This model mimics some of the physiological, behavioral changes, hypothetical pathogenesis and clinical pain features described in PTSD patients that includes enhanced negative feedback to the hypothalamic-pituitary-adrenal axis, anxiety-like behavior, cognitive impairments and memory dysfunction [23,24,38]. This model is also responsive to treatments showing some efficacy in alleviating visceral pain in IBS patients and therefore can predict treatment responses to specific drugs or nonpharmacological interventions in humans [9,12].

Previous animal studies have demonstrated that acute and chronic stress is associated with the development of allodynia, hyperalgesia or unaltered nociceptive sensitivity [17,18,39,40]. For example, 10–20 min forced swimming daily for 3 days induces hyperalgesia to thermal and chemical stimuli 8 to 9 days after the last swim session [17]. Exposure to water avoidance stress (WAS) for 1 h leads to a delayed visceral hyperalgesia to CRD, appearing 24 h after the end of the stress, and 10-day homotypic water avoidance stress induces visceral hypersensitivity that lasts for about 40 days [18]. Interestingly, exposure to a stressor stronger than WAS was found to induce an immediate hyperalgesia to CRD [41]. Moreover, the stress-related experimental models of IBS have demonstrated a lowered pain threshold and hyperalgesia to CRD [12,18,42-44]. In addition, female rats appear to show a different pattern of sensitized behavioral responsiveness to the same challenge, indicating sex-related alterations in the neuronal substrates involved in the responsiveness [12,41,44].

The present study demonstrated that there was a significant effect of SPS on VMR and AWR to distention, indicating that changes in visceral nociception and hyperalgesia differed over time between control and SPS rats. SPS-treated rats exhibited a temporary visceral analgesia within the initial 3 days following SPS exposure. Then, it was replenished on days 4 and 5, and returned to the baseline on day 6. SPS-induced analgesia on day 1 may be mediated by activation of the descending inhibitory pain pathway [45-47]. Pharmacological and neurochemical studies have demonstrated involvement of a large number of neurotransmitters and neuropeptides, such as endogenous

---

Figure 4: Effect of GF109203X (GF) at different doses on abdominal withdrawal reflex score in response to phasic colorectal distention at 40 mmHg (A) and 60 mmHg (B) following exposure to single-prolonged stress (SPS). All data are expressed as the mean ± S.E.M.

* P < 0.05, and ** P < 0.01, compared with SPS + Vehicle; # P < 0.05, compared with SPS + GF (0.5 nmol); & P < 0.01, compared with SPS + Vehicle.
opioid, monoamine, cannabinoid, g-aminobutyric acid and glutamate systems [45-47]. In addition, the present study showed down-regulation of PKCγ on day 1 after SPS, which may be another potential mechanism for stress-induced analgesia. These findings may enhance our understanding of the fundamental pathophysiology of SPS-induced visceral analgesia; however, further studies are required to determine whether the PKCγ signaling pathway can be a new therapeutic target for the treatment of stress-related functional gastrointestinal disorders.

In the present study, both VMR and AWR to CRD dramatically increased 7 days after initiation of SPS and the increased nociceptive responses were maintained for up to 28 days. However, visceral sensitivity did not differ within the control group over the 28 day period, indicating that the rats did not become sensitized to repeated CRD assessments over time. The development of the peripheral and central sensitization may be important in mediating stress-induced visceral hypersensitivity to CRD, in which maladaptive neuroplastic changes lead to persistently increased perception and response to noxious, or non-noxious stimuli [9,48,49]. Moreover, it has been reported that once peripheral and central sensitization has developed, it can in turn activate the release of spinal cord mediators such as acid-sensing ion channel 1a, neurokinin-1, and growth factors such as nerve growth factor or brain-derived neurotrophic factor and phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) as a result of stress exposure [22,50-52]. In the present study, PKCγ was up-regulated on days 7, 14, 21 and 28 after SPS in the spinal cord, indicating that it may also mediate the development of visceral hyperalgesia. Such alterations in the processing of visceral nociception are all considered as possible mechanisms of chronic visceral hyperalgesia following exposure to PTSD-like conditions.

The present study demonstrated that, concurrent with sustained visceral hyperalgesia, PKCγ protein expression in the dorsal horn neurons of the spinal cord was dramatically increased as early as 7 days after initiation of SPS and sustained for at least another three weeks. This finding indicates that PKCγ protein expression is consistently upregulated and thus PKCγ in the spinal...
cord is an important intracellular modulator that boosts neuronal activity in algesic and nociceptive signaling pathways. It is conceivable that PKCγ release and biosynthesis are accelerated following exposure to PTSD-like conditions, and the activation of PKCγ may produce an increased visceral nociceptive sensitivity. Although whether elevated PKCγ is a cause of the increased visceral nociceptive sensitivity needs further investigation, increased PKCγ expression at 28 day after initiation of SPS may reflect the broad spectrum of its roles in the development and maintenance of visceral hyperalgesia during PTSD. It is also implied the activation of PKCγ receptors contributes to the development of visceral pain hypersensitivity and hyperalgesia following exposure to PTSD-like stress. Therefore, the present study adds PKCγ to the list of key nociceptive molecules that participate in hypersensitivity in this model and underscores the fact that such visceral sensitization is accompanied by long lasting plasticity of sensory neurons in a PTSD-like stress state.

Figure 6 PKCγ protein expression by immunofluorescence in the spinal level over time following exposure to single prolonged stress. Representatives illustrating the distribution of PKCγ-immunoreactivity (IR) in the dorsal horn of control rats (A), and those day 1 (B), 7 (C), 14 (D) 21 (E), 28 (F), 9 (G) after exposure to SPS.
A previous study demonstrated that GF109203X, a PKCγ inhibitor, at 0.5 nmol/10 μL, a dose several fold higher than the ED50 [30], achieved a significant attenuation of muscle-induced mechanical hyperalgesia. In the present study, visceral nociceptive responses to CRD following exposure to PTSD-like stress was blocked by GF109203X at the spinal level, suggesting that PKCγ inhibitors may be neuroprotective in disorders with dysregulated PKCγ signaling following PTSD-like stress, and thus, supporting that spinal PKCγ activation plays a functional role in the development of visceral hypersensitivity, and enhanced responsiveness after SPS exposure is dependent on PKCγ activation. However, GF109203X had no significant effect on the VMR and AWR scores in control rats, suggesting that this agent did not act as a non-specific analgesic and the role of the PKCγ pathway in signaling colonic distention may not be as important in health as in the sensitized state.

There are several possibilities that could explain how PKCγ activation exerts its effects. First, this protein kinase is able to directly activate ERK1/2 members of the mitogen-activated protein kinases family, p38 and SAP/c-jun terminal kinase, which are involved in pain sensitization and several injury-activated pathways [53-55]. Second, spinal activation of PKCγ involves translocation from the cytosol.
to binding domains at cell membranes of dorsal horn neurons, increases release of glutamate in the spinal cord, and sensitizes the spinothalamic tract and other dorsal horn neurons, and formalin-induced release of glutamate is prevented by blockade of PKCγ [30,55-57]. Thus, PKCγ produces increased release of glutamate resulting in continued activation of glutamate receptors. Furthermore, spinal activation of PKCγ enhances responses of dorsal horn neurons to N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid agonists, which are involved in NMDA receptor-mediated mechanisms of visceral hyperalgesia. Also, spinal activation of PKCγ increases phosphorylation of the NMDA receptor subunit, NR1, and glutamate receptor subunit, GlurR1, which could result in an increased channel conductance and increase number of its receptors available in the membrane synaptically, resulting in increased excitation of the nociceptive spinal neurons [58-60]. Third, PKCγ decreases the effects of inhibitory neurotransmitters on spinothalamic tract neurons, which is manifested as an increased excitation and the increased PKCγ activity reduces normal inhibition within the spinal cord [61,62]. Therefore, this would result in increased excitability of neurons that is manifested as increased VMR and AWR scores to noxious stimuli.

Conclusions
The present study indicates that SPS alters visceral sensitivity to CRD, and contributes to the development and maintenance of delayed visceral hyperalgesia, which is associated with an enhanced PKCγ expression in the dorsal horn of the spinal cord. Functional blockade of PKCγ receptors attenuates SPS- induced visceral hyperalgesia. These data indicate that the large enhancement of PKCγ expression and function may contribute to the development and maintenance of visceral hyperalgesia. The present study provides direct evidence for a role of PKCγ in SPS- induced visceral pain, and thus may identify a specific molecular mechanism for visceral hyperalgesia which may pave the way for novel therapeutic strategies for PTSD-like conditions.

Methods
Animals
Experiments were performed on 8-week-old female Sprague–Dawley rats (220–300 g). The animals were housed under controlled conditions (21-25°C, 12/12 h light/dark cycle) with availability to standard rat chow and water ad libitum. Prior to the experiments, the animals were fasted for 18–24 h with free access to water. The study protocol with care and handling of these animals was approved by the Institutional Animal Care and Use Committee at the Third Military Medical University. Experiments were performed in accordance with the Guidelines of the International Association for the Study of Pain. Animals were allowed to acclimate for at least 7 days before experiments.

Intrathecal catheter implantation
Each of the rats was implanted with a chronic indwelling intrathecal catheter for drug or vehicle delivery. Briefly, animals were placed under general anesthesia using isoflurane inhalation (3.0%). A 23 G needle was inserted into the intrathecal space between L5 and L6 until a tail flick was elicited confirming intrathecal placement. A catheter was considered correctly placed if there was loss of sensory and motor function after injection of lidocaine. A gentamicin sulfate-flushed polyethylene (PE-10) tube was then inserted 4 cm deep so the tip was located for spinal lumbar enlargement. Once the catheter was secured to the fascia, the PE-10 tube was threaded out between the shoulder blades, and the incision was closed with wound clips. Rats were not tested for at least 7 days after surgery. Animals demonstrating motor dysfunction or dehydration immediately following surgery or at any point thereafter were euthanized.

Drug administration
Drugs were administered to the animals through the intrathecal catheter. A 30 G drug delivery needle attached to a PE-50 tube was affixed to the end of a 50 μL syringe. Drugs were delivered as a 10 μl bolus. For the behavioral experiment, GF109203X (Calbiochem, San Diego, CA), a specific PKC inhibitor, was dissolved in 10% dimethyl sulfoxide (DMSO). Then, GF109203X at different concentrations (0.05-0.50 nmol/10 μL) or vehicle (DMSO) was injected within 2 min directly into the lumbar spinal cord via the indwelling intrathecal catheter, and 10 min later, the number of AWR and EMG responses to CRD was measured as described below. SPS exposed rats were treated with one of four different doses of GF109203X alone (0.05, 0.15, 0.30 and 0.50 nmol/10 μL), and the dose–response effects of GF109023X were determined and the effective dose, which was defined as the dose that completely inhibits the response to 60 mmHg CRD, a noxious intensity, was identified for further experiments.

Modified single-prolonged stress for post-traumatic stress disorder
The detailed SPS procedure was performed as previously described [23,24] with modification. Briefly, animals were restricted in a disposable plastic holder (7 cm diameter, 21 cm in length) for 2 h, and then individually placed in a clear acrylic cylinder (20 cm diameter) filled to two thirds (35 cm) of its height with water (24°C) and forced to swim for 20 min, and following 15 min recuperation, exposed to inhalation of anesthetic isoflurane until the loss of consciousness. When they recovered
(approximately 30 min), the electric foot shock (1 mA for 4 s) was delivered via metal grids installed in the bottom of the chamber.

**Implantation of EMG electrodes**

Currently, the “gold standard” for assessing visceral nociceptive response is recording abdominal smooth muscle contractions, as a proxy to the VMR to CRD in conscious animals. In brief, rats were deeply anesthetized with sodium pentobarbital (45 mg/kg) administered intraperitoneally. Electrodes (Teflon-coated stainless steel wire, Cooner Wire, CA, USA) were stitched into the external oblique musculature, just superior to the inguinal ligament, for EMG recordings as previously described [63]. The electrode leads were then tunneled subcutaneously and externalized laterally through the skin of the abdomen and neck for future access. The incisions were closed with wound clips. Wounds were tested for tenderness to ensure complete recovery from surgery before behavioral testing as described below.

**Behavioral Testing for Nocifensive Responses**

**Visceromotor responses**

Visceral sensitivity was measured by grading behavioral response of rats to phasic CRD as previously described [63-65] before initiation of SPS (on day 0, as baseline) and at various time points (on days 1, 6, 7, 9, 14, 21, 28 and 29) in rats exposed to SPS. Briefly, after an overnight fast, the rats were anesthetized using isoflurane inhalation (3.0%). A flexible latex balloon (5 cm) attached to a tygon tube was inserted 8 cm into the descending colon and rectum via the anus and held in place by tapping the tubing to the base of the tail. After the rat regained consciousness, the rat was allowed to adapt for 30 min prior to CRD. Attachment of a strain gauge force transducer to the abdominal oblique muscle allowed direct monitoring of the muscle contractile activity, and CRD was performed by rapidly inflating the balloon to a constant pressure with a pressure control device (Micro-1401, CED, UK). The distension protocol consisted of a series of phasic CRD to constant pressures of 1, 20, 40, and 60 mmHg, for 20 seconds followed by a 4 min interstimulus interval [64]. To examine the pressure-response relationship, the EMG activity was rectified, and the increase in the AUC of EMG amplitude (over baseline) was recorded as previously described [65].

**Abdominal withdrawal reflex**

Behavioral response to CRD was also measured by visual observation of the AWR, as previously described [13]. The AWR were scored as follows: 0, no behavioral response to CRD; 1, brief head movement followed by immobility; 2, contraction of abdominal muscles; 3, lifting of abdomen; and 4, body arching and lifting of pelvic structures. During testing, the observers were completely blinded to the training conditions.

**Western blotting**

Animals were anesthetized with 4% isoflurane and decapitated, and the lumbar sacral spinal cord segment was dissected. The tissue, weighing 20 mg, was homogenized in 100 µL of lysis buffer containing 50 mM Tris–HCl pH 8.0, 150 mM NaCl, 1 mM ethylenediamine-N,N,N',N'-tetra-acetic acid (EDTA), 0.5% Triton X-100 and a complete protease inhibitor. The homogenate was incubated on ice for 30 min and then the suspension was sonicated on ice using three 10-second bursts at high intensity with a 10-second cooling period between each burst. The samples were centrifuged at 13000 rpm for 15 min at 4°C and the supernatant was collected and stored at –80°C. The protein concentrations were determined by the BCA Protein Assay Kit as described by the manufacturer. Each protein sample (60 µg) was loaded in 8% sodium dodecyl sulfate-polyacrylamide gel (Bio-Rad), by electrophoresis and then transferred to polyvinylidene fluoride membranes. The membranes were blocked with 5% non-fat dry milk in Tris-buffered saline with 0.5% Tween-20 (TBST) buffer at room temperature for 1 h and incubated with the primary antibody (PKCγ, at 1:1000, Abcam) overnight at 4°C. After washing in TBST, the membranes were incubated with the secondary antibody [horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG] in 3% milk-TBST (1:3,000 dilution) for 2 h at room temperature. After washing with TBST three times, the HRP-antibody signal was detected by the electrochemiluminescence (ECL) kit from Amersham (GE Healthcare, Piscataway, NJ, USA), followed by exposure to Kodak X-ray film. The membranes were subsequently stripped and re-probed for anti-β-actin antibody (1: 1000, Santa Cruz). Films were scanned and the intensity of PKCγ immunoreactive bands was quantified using Bio-Rad Quantity One software and normalized relative to the intensity of the β-actin immunoreactive band.

**Immunofluorescence staining**

For PKCγ immunofluorescence staining, animals were anesthetized with sodium pentobarbital (45 mg/kg) administered intraperitoneally and perfused transcardially with 150 mL phosphate-buffered saline (PBS) followed by 400 mL ice-cold 4% paraformaldehyde (PFA) in phosphate buffer (PB), pH 7.4. Spinal cords were removed and postfixed for 4 h in PFA and transferred to 30% sucrose overnight in PB for cryoprotection, and then cut using a cryostat at 30 µm in thickness. The immunostainings were performed using the ‘free floating’ technique for the spinal cord. Briefly, the sections were blocked for 1 h in blocking buffer (10% donkey serum) at room temperature, and then anti-PKCγ antibody (diluted 1:1000, Abcam) was added overnight at room temperature. After washing three times
with TBST at room temperature, the slides were incubated with the following secondary antibodies (Cy3, Invitrogen, diluted 1:200) for 1 h at room temperature. Images were viewed and captured using a BX50 Olympus microscope (Center Valley, PA), using Image-Pro Plus software 6.0 (USA) to analyze the immunofluorescence staining.

Data analysis
Statistical analyses of the data were performed on the computer using the software PASW 17.0 (Chicago, Illinois, USA). All numerical data were expressed as the mean ± standard error of mean (S.E.M.) and statistical significance was determined by the student t-test or analysis of variance (ANOVA) test, followed by the least significant difference multiple comparison post hoc test. P values of less than 0.05 were considered statistically significant.

Abbreviations
AOD: Average optical density; AUC: Area under the curve; AWR: Abdominal withdrawal reflex; CRD: Colorectal distention; DMSO: Dimethyl sulfoxide; EMG: Electromyographic; HRP: Horseradish peroxidase; IBS: Irritable bowel syndrome; PB: Phosphate buffer; PBS: Phosphate-buffered saline; PPA: Paraformaldehyde; PKCγ: Protein kinase C gamma; PTSD: Post-traumatic stress disorder; VMR: Visceromotor response; ROD: Relative optical density; SPS: Single-prolonged stress; WAS: Water avoidance stress.

Competing interests
The authors declare that they have no financial or nonfinancial competing interests.

Authors’ contributions
Y-QF, QC and LJ contributed equally to this paper. All authors read and approved the final manuscript.

Acknowledgements
This work was supported by grants from the Natural Science Foundation of China (No. 30700362/H0307 and No. 81070298/H0307), National Natural Science Foundation Key Program of Chongqing (CSTC 2008BB5108), Natural Science Foundation Key Program of Chongqing (CSTC 2011–1700), and the Scientific Research Foundation for Returned Overseas Chinese Scholars. We are grateful to Mr. Zaiyun Long for expert technical assistance.

Author details
1. Department of Gastroenterology, Daping Hospital, Third Military Medical University, 10 Changjiang Branch Road, Daping, Chongqing 400042, China. 2. School of Psychology, Southwest University, Beibei, Chongqing 400715, China. 3. Department of Physiology and Cell Biology, The Ohio State University, 43210, Columbus, Ohio, USA.

Received: 2 March 2013 Accepted: 4 July 2013
Published: 9 July 2013

References
1. Javidi H, Yaloddahie M: Post-traumatic Stress Disorder. Int J Occup Environ Med 2012, 3(1):2–9.
2. Nemec-Moro I, Franciskovic T, Brichta D, Karic M, Zecевич I: Disorder of extreme stress not otherwise specified (DESNOS) in Croatian war veterans with posttraumatic stress disorder: case–control study. Croat Med J 2011, 52(4):505–12.
3. Stevens NR, Gerhart J, Goldsmith RE, Heath NM, Cheney SA, Hobfoll SE: Emotion regulation difficulties, low social support, and interpersonal violence mediate the link between childhood abuse and posttraumatic stress symptoms. Behav Ther 2013; 44(1):52–61.
4. Cohen H, Jotkowitz A, Buskila D, Pellegr-Avari A, Kaplan Z, Neumann L, Speerber AD: Post-traumatic stress disorder and other co-morbidities in a sample population of patients with irritable bowel syndrome. Eur J Intern Med 2006, 17(8):567–71.
5. White DL, Savas LS, Daci K, Elserag R, Graham DP, Fitzgerald SJ, Smith SL, Tan G, El-Serag HB: Trauma history and risk of the irritable bowel syndrome in women veterans. Aliment Pharmacol Ther 2010, 32(4):551–61.
6. Aichacher K, Otis JD: Significant others’ responses to pain in veterans with chronic pain and clinical levels of post-traumatic stress disorder symptomatology. Eur J Pain 2013, 17(1):245–54.
7. Gibson CA: Review of posttraumatic stress disorder and chronic pain: the path to integrated care. J Rehabil Res Dev 2012, 49(5):753–76.
8. Moeller-Bertram T, Kelmter J, Strigo IA: Pain and post traumatic stress disorder-review of clinical and experimental evidence. Neuropsychopharmacology 2012, 37(2):586–91.
9. Larache M, Mulak A, Tache Y: Stress and visceral pain: from animal models to clinical therapies. Exp Neurol 2012, 233(1):49–67.
10. Roth ML, St Cyt K, Harle I, Kutz JD: Relationship between pain and post-traumatic stress symptoms in palliative care. J Pain Symptom Manage 2012. doi:10.1016/j.painsymman.2012.07.015.
11. Strigo IA, Simmons AN, Matthews SC, Grimes EM, Allard CB, Reinhardt LE, Paulus MP, Stein MB: Neural correlates of altered pain response in women with posttraumatic stress disorder from intimate partner violence. Biol Psychiatry 2010, 68(5):442–50.
12. Larache M, Mulak A, Tache Y: Stress-related alterations of visceral sensation: animal models for irritable bowel syndrome study. Neurogastroenterol Motil 2011, 13(3):231–34.
13. Wang YX, Xu F, Hu S, Xiao Y, Jiang X, Xu GY: Upregulation of cystathionine β-synthetase expression contributes to visceral hyperalgesia induced by heterotypic intermittent stress in rats. PLoS One 2012, 7(12):e53165.
14. Bremner JD, Elzinga B, Schnall C, Vernetten E: Structural and functional plasticity of the human brain in posttraumatic stress disorder. Prog Brain Res 2008, 176:171–86.
15. Cui H, Sakamoto H, Higashi S, Kawata M: Effects of single-prolonged stress on neurons and their afferent inputs in the amygdala. Neuroscience 2008, 152(3):703–12.
16. Li XM, Han F, Liu DJ, Shi XY: Single-prolonged stress induced mitochondrial-dependent apoptosis in hippocampus in the rat model of post-traumatic stress disorder. J Chem Neuroanat 2010, 40(3):248–55.
17. Quintero L, Moreno M, Avila C, Arcaya J, Maier W, Suarez-Roca H: Long-lasting delayed hyperalgesia after subchronic swim stress. Pharmacol Biochem Behav 2000, 67(3):449–58.
18. Winsston JT, Xu GY, Saka SM: Adrenergic stimulation mediates visceral hypersensitivity to colorectal distension following heterotypic chronic stress. Gastroenterology 2010, 138(1):294–304.
19. Peng HY, Hsieh WC, Lai CY, Chen GQ, Huang YP, Lin BC: Glucocorticoid mediates water avoidance stress-sensitized colonic-bladder cross-talk via RSK2/P38/p56Lck and P2X3/β2-hexosaminidase 2 in rats. J Physiol Endocrinol Metab 2012; 368(3):104–108.
20. Quintero L, Cardenas R, Suarez-Roca H: Stress-induced hyperalgesia is associated with a reduced and delayed GABA inhibitory control that enhances post-synaptic NMDA receptor activation in the spinal cord. Pain 2011, 152(8):1909–22.
21. Robbins MT, Deberry J, Randich A, Ness TJ: Footshock stress differentially affects responses of two subpopulations of spinal dorsal horn neurons to urinary bladder distension in rats. Brain Res 2011, 1386(1):15–26.
22. Tsang SW, Zhao M, Wu J, Sung JJ, Bian XZ: Nerve growth factor-mediated neuropeptide expression in spinal cord in rats contributes to neonatal maternal separation-induced visceral hypersensitivity in rats. Eur J Pain 2012, 16(4):463–72.
23. Wang HN, Peng Y, Tan QR, Chen YC, Zhang RG, Qiao YT, Wang HH, Liu L, Huang F, Wang BR, Zhang ZL: Quetiapine ameliorates anxiety-like behavior and cognitive impairments in stressed rats: implications for the treatment of posttraumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010, 35(2):263–71.
24. Wang W, Liu Y, Zheng H, Wang HM, Jin X, Chen YC, Zheng LN, Luo XX, Tan QR: A modified single prolonged stress model for post-traumatic stress disorder. Neurosci Lett 2008, 441(2):237–41.
25. Hughes AS, Averill S, King VR, Molander C, Shortland PJ: Neurochemical characterization of neuronal populations expressing protein kinase C gamma isoform in the spinal cord and gracile nucleus of the rat. Neuroscience 2008, 153(2):507–17.
26. Song Z, Zou W, Liu C, Guo G: Gene knockdown with lentiviral vector-mediated intrathecal RNA interference of protein kinase C gamma reverses chronic morphine tolerance in rats. J Gene Med 2010, 12(11):573–80.
Induction of vanilloid receptor channel activity by protein kinase C. Nature 2000, 4(815):985–990.

Villarreal CF, Sachs D, Funke ML, Parada CA, De Queiroz CF, Ferreira SH: The peripheral nociceptive state induced by repetitive inflammatory stimuli involves continuous activation of protein kinase A and protein kinase C epsilon and its Na(V)1.8 sodium channel functional regulation in the primary sensory neuron. Biochem Pharmacol 2009, 77(1):867–77.

Malmberg AB, Chen C, Tonegawa S, Basbaum AI: The effects of G-protein and protein kinase inhibitors on the behavioral responses of rats to intradermal injection of capsaicin. Pain 1997, 71(2):165–78.

Zhang LP, Zhang X, Westlund KN: The peripheral pro-nociceptive state induced by repetitive inflammatory stimuli. Eur J Pain 2011, 15(4):335–43.

Bradesi S, Svensson CI, Steinauer J, Pothoulakis C, Yaksh TL, Mayer EA: Role of spinal microglia in visceral hypersensitivity and NK1R up-regulation in a rat model of chronic stress. Gastroenterology 2009, 136(4):1339–48.

Cruz GD, Cruz FA: The ERK 1 and 2 pathway in the nervous system: from basic aspects to possible clinical applications in pain and visceral dysfunction. Curr Neuropathol 2007, 5(4):244–52.

Di Cesare ML, Ghelardini C, Tocasano A, Pacini A, Bartolini A: The neuropathy-protective agent acetylc-L-carnitine activates protein kinase C-gamma and MAPKs in a rat model of neuropathic pain. Neuroscience 2010, 165(5):1345–52.

Gregus AM, Inra CN, Giordano TP, Costa AC, Rajadhyaksha AM, Inturriese C: Spinal mediators that may contribute selectively to antinociceptive tolerance but not other effects of morphine as revealed by deletion of GluR5. Neurosci 2010, 169(1):475–87.

Kohno T, Wang H, Amaya F, Brenner GJ, Cheng JK, Ji RR, Woolf CJ: Bradykinin enhances AMPA and NMDA receptor activity in spinal cord dorsal horn neurons by activating multiple kinases to produce pain hypersensitivity. J Neurosci 2008, 28(17):4533–40.

Giles PA, Treutle DJ, King AE: Differential activation of protein kinases in the dorsal horn in vitro of normal and inflamed rats by group I metabotropic glutamate receptor subtypes. Neuropharmacology 2007, 53(1):58–70.

Yeh CT, Chung SC, Tseng FL, Tsai YC, Liu YC: Biphasic effects of chronic intragastric gabapentin administration on the expression of protein kinase C gamma in the spinal cord of neuropathic pain rats. Acta Anaesthesiol Taiwan 2011, 49(1):44–8.

Roh DH, Choi SR, Yoon SY, Kang SY, Moon JK, Kwon SG, Han HI, Beitz AJ, Lee JH: Spinal neuronal NOS activation mediates sigma-1 receptor-induced mechanical and thermal hypersensitivity in mice: involvement of PKC-dependent GluN1 phosphorylation. Br J Pharmacol 2011, 163(8):707–20.

Yan JZ, Xu Z, Ren SQ, Hu B, Yao W, Wang SH, Liu SY, Lu W: Protein kinase C promotes N-methyl-D-aspartate (NMDA) receptor trafficking by indirectly triggering calcium/calmodulin-dependent protein kinase II (CaMKII) autophosphorylation. J Biol Chem 2011, 286(28):24187–200.

Yang Y, Roman K, Chen DK, Wang ZG, Lin Y, Stephens RL Jr: GLT-1 overexpression attenuates bladder nociception and local/cross-organ sensitization of bladder nociception. Am J Physiol Renal Physiol 2011, 300(6):F1533–9.

Lee JJ, Hahm ET, Min BI, Cho YW: Activation of protein kinase C antagonizes the opioid inhibition of calcium current in rat spinal dorsal horn neurons. Brain Res 2004, 1017(1):2198–19.

Lin Q, Peng YB, Willis WD: Inhibition of primate spinointraxial spinal neurons by spinal glycin and GABA is reduced during central sensitization. J Neurophysiol 1996, 76(2):1005–14.

Sohn CI, Park HJ, Gebhart GF: Adenosine receptor agonists modulate visceral hypersensitivity in the rat. Gut Liver 2008, 2(1):39–46.

Larache M, Gourcerol G, Wang L, Pambukchian K, Brunnhuber S, Adelson DW, Rivier J, Million M, Taché Y: Cortagine, a CRF1 agonist, induces stresslike alterations of colonic function and visceral hypersensitivity in rodents primarily through peripheral pathways. Am J Physiol Gastrointest Liver Physiol 2009, 297(1):G215–27.

Schwetz I, Bradesi S, McRoberts JA, Sablad M, Miller JC, Zhou H, Ohning G, Mayer EA: Delayed stress-induced colonic hypersensitivity in male Wistar rats: role of neurokinin-1 and corticotropin-releasing factor-1 receptors. Am J Physiol Gastrointest Liver Physiol 2004, 286(6):G683–91.

Gosselin RD, O’Connor RM, tramullas M, julio-pieper M, dinan TG, cryan JF: Riluzole normalizes early-life stress-induced visceral hypersensitivity in rats: role of spinal glutamate reuptake mechanisms. Gastroenterology 2010, 138(7):2418–25.

Azpiroz F, Bouin M, Camillieri M, Mayer EA, Potras P, Serra J, Spiller RC: Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil 2007, 19(1):Suppl 62–88.

Sengupta JN: Visceral pain: the neurophysiological mechanism. Handb Exp Pharmacol 2009, 194:61–74.

Mattoon JC, geleot A, etienne M, lazdunski M, Muller E, ardil D: Spinal cord plasticity and acid-sensing ion channels involvement in a rodent model of irritable bowel syndrome. Eur J Pain 2011, 15(4):335–43.

Bradesi S, svensson CI, steinauer J, pothoulakis C, yakash TL, Mayer EA: Role of spinal microglia in visceral hypersensitivity and Nk1r up-regulation in a rat model of chronic stress. Gastroenterology 2009, 136(4):1339–48.

Cruz GD, cruz FA: The Erk 1 and 2 pathway in the nervous system: from basic aspects to possible clinical applications in pain and visceral dysfunction. Curr Neuropathol 2007, 5(4):244–52.

Di Cesare ML, Ghelardini C, Tocasano A, Pacini A, Bartolini A: The neuropathy-protective agent acetylc-L-carnitine activates protein kinase C-gamma and MAPKs in a rat model of neuropathic pain. Neuroscience 2010, 165(5):1345–52.

Gregus AM, Inra CN, Giordano TP, Costa AC, Rajadhyaksha AM, Inturriese C: Spinal mediators that may contribute selectively to antinociceptive tolerance but not other effects of morphine as revealed by deletion of GluR5. Neuroscience 2010, 169(1):475–87.

Kohno T, Wang H, Amaya F, Brenner GJ, Cheng JK, Ji RR, Woolf CJ: Bradykinin enhances AMPA and NMDA receptor activity in spinal cord dorsal horn neurons by activating multiple kinases to produce pain hypersensitivity. J Neurosci 2008, 28(17):4533–40.

Giles PA, Treutle DJ, King AE: Differential activation of protein kinases in the dorsal horn in vitro of normal and inflamed rats by group I metabotropic glutamate receptor subtypes. Neuropharmacology 2007, 53(1):58–70.

Yeh CT, Chung SC, Tseng FL, Tsai YC, Liu YC: Biphasic effects of chronic intragastric gabapentin administration on the expression of protein kinase C gamma in the spinal cord of neuropathic pain rats. Acta Anaesthesiol Taiwan 2011, 49(1):44–8.

Roh DH, Choi SR, Yoon SY, Kang SY, Moon JK, Kwon SG, Han HI, Beitz AJ, Lee JH: Spinal neuronal NOS activation mediates sigma-1 receptor-induced mechanical and thermal hypersensitivity in mice: involvement of PKC-dependent GluN1 phosphorylation. Br J Pharmacol 2011, 163(8):707–20.

Yan JZ, Xu Z, Ren SQ, Hu B, Yao W, Wang SH, Liu SY, Lui W: Protein kinase C promotes N-methyl-D-aspartate (NMDA) receptor trafficking by indirectly triggering calcium/calmudulin-dependent protein kinase II (CaMKII) autophosphorylation. J Biol Chem 2011, 286(28):24187–200.

Yang Y, Roman K, Chen DK, Wang ZG, Lin Y, Stephens RL Jr: GLT-1 overexpression attenuates bladder nociception and local/cross-organ sensitization of bladder nociception. Am J Physiol Renal Physiol 2011, 300(6):F1533–9.

Lee JJ, Hahm ET, Min BI, Cho YW: Activation of protein kinase C antagonizes the opioid inhibition of calcium current in rat spinal dorsal horn neurons. Brain Res 2004, 1017(1):2198–19.

Lin Q, Peng YB, Willis WD: Inhibition of primate spinach motranthal spinal neurons by spinal glycin and GABA is reduced during central sensitization. J Neurophysiol 1996, 76(2):1005–14.

Sohn CI, Park HJ, Gebhart GF: Adenosine receptor agonists modulate visceral hypersensitivity in the rat. Gut Liver 2008, 2(1):39–46.

Larache M, Gourcerol G, Wang L, Pambukchian K, Brunnhuber S, Adelson DW, Rivier J, Million M, Taché Y: Cortagine, a CRF1 agonist, induces stresslike alterations of colonic function and visceral hypersensitivity in rodents primarily through peripheral pathways. Am J Physiol Gastrointest Liver Physiol 2009, 297(1):G215–27.

Schwetz I, Bradesi S, McRoberts JA, Sablad M, Miller JC, Zhou H, Ohning G, Mayer EA: Delayed stress-induced colonic hypersensitivity in male Wistar rats: role of neurokinin-1 and corticotropin-releasing factor-1 receptors. Am J Physiol Gastrointest Liver Physiol 2004, 286(6):G683–91.